Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Engage Plus Grants Program

Université de Montréal

$12,500.00

Development of a nystatin nanosuspension formulation using high pressure homogenisation

FY 2015-16

Summary
Nystatin is the current treatment of choice for Oropharyngeal candidiasis (OPC), a common fungal infection of the oral cavity. Poorly soluble nystatin is formulated as a suspension intended for local application. The bioavailability of the active ingredient after oral administration is limited and principally eliminated in the faeces. Nanosizing of poorly soluble drugs has been reported as an attractive approach to improve their efficacy after oral administration. A previous publication showed that nanosizing provides a promising approach to increasing the efficacy of topically administered nystatin in the treatment of OPC. A foregoing formulation screening of nystatin using three different nanomilling processes showed that high pressure homogenisation technique offered a better milling yield than the wet milling while the size of 90% of particles in the obtained suspension were smaller than 1.9 µm. The goal of the present project is to explore new formulations of nystatin suspension in order to obtain better results in terms of particle size and physical stability, using the high pressure homogeniser. The new formulations will be compared with the commercial nystatin suspension milled in the same conditions. The chemical stability, the physicochemical stability, the presence of residual contamination and the nanoparticle aggregation will be assessed during the long-term stability study of the promising formulation of nystatin nanosuspension.
Program
Engage Plus Grants Program
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data

As published

Application id
486974-2015
Name nom
Leclair, Grégoire
Department département
Pharmacie, faculté de
Organization id
63
Institution établissement
Université de Montréal
Province en
Québec
Province fr
Québec
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2015
Competition year année de concours
2015
Award amount
12500
Program id
EGP2
Program name en
Engage Plus Grants Program
Program name fr
Programme de subvention d'engagement partenarial Plus
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
1552
Committee name en
Quebec Internal Decision Committee
Committee name fr
Comité de décision interne pour le Québec
Area of application code
504
Area of application group en
Manufacturing processes and products
Area of application group fr
Procédés et produits industriels
Area of application en
Human pharmaceuticals
Area of application fr
Produits pharmaceutiques administrables à l'homme
Research subject code
1800
Research subject group en
Chemical engineering
Research subject group fr
Génie chimique
Research subject en
Chemical engineering
Research subject fr
Génie chimique
Partie
1
Nb partie
1
Application title
Development of a nystatin nanosuspension formulation using high pressure homogenisation
Keyword
NSERC
Application summary
Nystatin is the current treatment of choice for Oropharyngeal candidiasis (OPC), a common fungal infection of the oral cavity. Poorly soluble nystatin is formulated as a suspension intended for local application. The bioavailability of the active ingredient after oral administration is limited and principally eliminated in the faeces. Nanosizing of poorly soluble drugs has been reported as an attractive approach to improve their efficacy after oral administration. A previous publication showed that nanosizing provides a promising approach to increasing the efficacy of topically administered nystatin in the treatment of OPC. A foregoing formulation screening of nystatin using three different nanomilling processes showed that high pressure homogenisation technique offered a better milling yield than the wet milling while the size of 90% of particles in the obtained suspension were smaller than 1.9 µm. The goal of the present project is to explore new formulations of nystatin suspension in order to obtain better results in terms of particle size and physical stability, using the high pressure homogeniser. The new formulations will be compared with the commercial nystatin suspension milled in the same conditions. The chemical stability, the physicochemical stability, the presence of residual contamination and the nanoparticle aggregation will be assessed during the long-term stability study of the promising formulation of nystatin nanosuspension.